IFITM1 and chronic myelogenous leukemia, BCR-ABL1 positive: In particular, IFITM1 overexpression has been shown to inhibit proliferation in hepatoma cells [29] and its constitutive overexpression has been shown to positively correlate with improved survival in chronic myeloid leukemia patients [25].